Host intestinal immune signaling

Host intestinal immune signaling refers to the integrated network of molecular pathways that regulate the immune response within the gastrointestinal tract, maintaining a delicate balance between tolerance to commensal microbes and defense against pathogens (Mowat & Agace, 2014). This signaling involves various components, including pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) and NOD-like receptors (NLRs), which detect microbial signals and initiate downstream cascades (Abraham & Medzhitov, 2011). Key signaling molecules include cytokines such as Tumor Necrosis Factor (TNF), Interleukin-12 (IL-12), and Interleukin-23 (IL-23), which coordinate the activity of T-cells, B-cells, and innate lymphoid cells (Neurath, 2014). Dysregulation of these pathways is a hallmark of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, where excessive or inappropriate signaling leads to chronic mucosal inflammation (Danese & Fiocchi, 2011). While host intestinal immune signaling is a broad biological process rather than a single therapeutic target, many successful drugs act by specifically inhibiting individual nodes within this network, such as TNF-alpha inhibitors or integrin antagonists (Ungaro et al., 2017). These therapies aim to restore immune homeostasis and promote mucosal healing in patients with chronic inflammatory conditions (Neurath, 2017).

Other names

Intestinal mucosal immunityGut immune signalingGastrointestinal immune responseIntestinal immune homeostasis

Modulation of the immune response through the inhibition of specific pro-inflammatory cytokines, blockade of lymphocyte trafficking to the gut mucosa, or interference with intracellular signaling pathways such as the JAK-STAT pathway (Neurath, 2014; Ungaro et al., 2017).